Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population

Chia Wen Lu, Chih-Jen Chang, Yi-Ching Yang, Wen Yuan Lin, Kuo Chin Huang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: This study aimed to evaluate the effects of lorcaserin on body weight, cardiovascular risk factors, and safety in obese patients in Taiwan. Methods: In this double-blind, randomised controlled trial, 171 obese adults were assigned to receive lorcaserin at a dose of 10 mg, or placebo, twice a day for 24 weeks. Diet and exercise counselling were given to all patients through the treatment period. Primary outcomes were proportion of patients achieving at least 5% and 10% reduction in body weight and mean change in body weight. Safety and tolerability endpoints such as Beck Depression Inventory-II, blood biochemistry, vital signs, and electrocardiogram were monitored. Results: More patients receiving lorcaserin lost at least 5% body weight than receiving placebo (52.4% and 28.1%, P = 0.001) with an average weight reduction of 5.8 kg (95% CI: −6.91, −4.70) in lorcaserin group and those of 3.6 kg (95% CI: −4.95, −2.33) in placebo group (P < 0.05). The most common adverse effect with greater incidence in the lorcaserin group was self-limited dizziness. Serious adverse effect were rare and was reported by slightly more patients taking placebo than lorcaserin. Conclusions: In this multicentre, double-blinded placebo-controlled trial, lorcaserin was effective and well-tolerable in Asia group.

Original languageEnglish
Pages (from-to)465-471
Number of pages7
JournalObesity Research and Clinical Practice
Volume12
Issue number5
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Placebos
Weights and Measures
Population
Body Weight
Safety
Body Weight Changes
Vital Signs
Dizziness
lorcaserin
Taiwan
Double-Blind Method
Biochemistry
Counseling
Weight Loss
Electrocardiography
Randomized Controlled Trials
Exercise
Depression
Diet
Equipment and Supplies

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

@article{12efec3c777c4f1391c14528289faf32,
title = "Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population",
abstract = "Objective: This study aimed to evaluate the effects of lorcaserin on body weight, cardiovascular risk factors, and safety in obese patients in Taiwan. Methods: In this double-blind, randomised controlled trial, 171 obese adults were assigned to receive lorcaserin at a dose of 10 mg, or placebo, twice a day for 24 weeks. Diet and exercise counselling were given to all patients through the treatment period. Primary outcomes were proportion of patients achieving at least 5{\%} and 10{\%} reduction in body weight and mean change in body weight. Safety and tolerability endpoints such as Beck Depression Inventory-II, blood biochemistry, vital signs, and electrocardiogram were monitored. Results: More patients receiving lorcaserin lost at least 5{\%} body weight than receiving placebo (52.4{\%} and 28.1{\%}, P = 0.001) with an average weight reduction of 5.8 kg (95{\%} CI: −6.91, −4.70) in lorcaserin group and those of 3.6 kg (95{\%} CI: −4.95, −2.33) in placebo group (P < 0.05). The most common adverse effect with greater incidence in the lorcaserin group was self-limited dizziness. Serious adverse effect were rare and was reported by slightly more patients taking placebo than lorcaserin. Conclusions: In this multicentre, double-blinded placebo-controlled trial, lorcaserin was effective and well-tolerable in Asia group.",
author = "Lu, {Chia Wen} and Chih-Jen Chang and Yi-Ching Yang and Lin, {Wen Yuan} and Huang, {Kuo Chin}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.orcp.2018.07.007",
language = "English",
volume = "12",
pages = "465--471",
journal = "Obesity Research and Clinical Practice",
issn = "1871-403X",
publisher = "Elsevier BV",
number = "5",

}

Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population. / Lu, Chia Wen; Chang, Chih-Jen; Yang, Yi-Ching; Lin, Wen Yuan; Huang, Kuo Chin.

In: Obesity Research and Clinical Practice, Vol. 12, No. 5, 01.09.2018, p. 465-471.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population

AU - Lu, Chia Wen

AU - Chang, Chih-Jen

AU - Yang, Yi-Ching

AU - Lin, Wen Yuan

AU - Huang, Kuo Chin

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Objective: This study aimed to evaluate the effects of lorcaserin on body weight, cardiovascular risk factors, and safety in obese patients in Taiwan. Methods: In this double-blind, randomised controlled trial, 171 obese adults were assigned to receive lorcaserin at a dose of 10 mg, or placebo, twice a day for 24 weeks. Diet and exercise counselling were given to all patients through the treatment period. Primary outcomes were proportion of patients achieving at least 5% and 10% reduction in body weight and mean change in body weight. Safety and tolerability endpoints such as Beck Depression Inventory-II, blood biochemistry, vital signs, and electrocardiogram were monitored. Results: More patients receiving lorcaserin lost at least 5% body weight than receiving placebo (52.4% and 28.1%, P = 0.001) with an average weight reduction of 5.8 kg (95% CI: −6.91, −4.70) in lorcaserin group and those of 3.6 kg (95% CI: −4.95, −2.33) in placebo group (P < 0.05). The most common adverse effect with greater incidence in the lorcaserin group was self-limited dizziness. Serious adverse effect were rare and was reported by slightly more patients taking placebo than lorcaserin. Conclusions: In this multicentre, double-blinded placebo-controlled trial, lorcaserin was effective and well-tolerable in Asia group.

AB - Objective: This study aimed to evaluate the effects of lorcaserin on body weight, cardiovascular risk factors, and safety in obese patients in Taiwan. Methods: In this double-blind, randomised controlled trial, 171 obese adults were assigned to receive lorcaserin at a dose of 10 mg, or placebo, twice a day for 24 weeks. Diet and exercise counselling were given to all patients through the treatment period. Primary outcomes were proportion of patients achieving at least 5% and 10% reduction in body weight and mean change in body weight. Safety and tolerability endpoints such as Beck Depression Inventory-II, blood biochemistry, vital signs, and electrocardiogram were monitored. Results: More patients receiving lorcaserin lost at least 5% body weight than receiving placebo (52.4% and 28.1%, P = 0.001) with an average weight reduction of 5.8 kg (95% CI: −6.91, −4.70) in lorcaserin group and those of 3.6 kg (95% CI: −4.95, −2.33) in placebo group (P < 0.05). The most common adverse effect with greater incidence in the lorcaserin group was self-limited dizziness. Serious adverse effect were rare and was reported by slightly more patients taking placebo than lorcaserin. Conclusions: In this multicentre, double-blinded placebo-controlled trial, lorcaserin was effective and well-tolerable in Asia group.

UR - http://www.scopus.com/inward/record.url?scp=85050116663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050116663&partnerID=8YFLogxK

U2 - 10.1016/j.orcp.2018.07.007

DO - 10.1016/j.orcp.2018.07.007

M3 - Article

C2 - 30033356

AN - SCOPUS:85050116663

VL - 12

SP - 465

EP - 471

JO - Obesity Research and Clinical Practice

JF - Obesity Research and Clinical Practice

SN - 1871-403X

IS - 5

ER -